| abstract |
The presently disclosed subject matter provides methods and compositions for treating cancer (e.g., pancreatic cancer). It relates to antigen recognition receptors (e.g., Chimeric Antigen Receptors (CARs)) that specifically target sialyl lewis a (e.g., human sialyl lewis a), and immunoresponsive cells comprising such CARs. Sialyl lewis a-specific CARs of the present disclosure have enhanced immune activation properties, including anti-tumor activity. |